Company profile
Actuate Therapeutics, Inc.
Pipeline1 asset
- elraglusib9-ING-41 / GSK-3β / small molecule inhibitor / Oncology1L metastatic pancreatic cancer with gemcitabine/nab-paclitaxelPhase 2ongoing; Actuate-1801 Part 3BUSEUCanada1L metastatic pancreatic cancer with gemcitabine/nab-paclitaxelPhase 3in planning; registration trial contingent on funding1L metastatic pancreatic cancer with FOLFIRINOXPhase 2investigator-initiated; closed to enrollment